EIR availability to manufacturers could prevent inappropriate warning letters, MDMA counsel Pilot says.
This article was originally published in The Gray Sheet
GMP INSPECTION REPORT AVAILABILITY TO FIRMS PRIOR TO FDA ENFORCEMENT DECISION could help prevent inappropriate warning letters, Larry Pilot, McKenna & Cuneo attorney and counsel to the Medical Device Manufacturers Association, says in a May 24 letter to FDA. "Many manufacturers have experienced the trauma of a warning letter because of incorrect and uncontradicted statements made in" an establishment inspection report, Pilot says in the letter to Joseph Levitt, deputy director for regulations and policy at FDA's Center for Devices and Radiological Health. "These unfortunate experiences...could have been avoided if the manufacturer had access to and the opportunity to comment on the EIR prior to any enforcement decision by FDA."
You may also be interested in...
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.
CMS acknowledges stakeholders may need more details about the plan before it is finalized and a delay will give the agency more time to ‘consider the issue.’
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.